 |
市場調查報告書
商品編碼
1473789
頭孢菌素藥物市場- 依代（第一、第二）、適應症（呼吸道、泌尿道感染、性傳染感染、胃腸道感染）、給藥途徑（口服、腸胃外、局部）、型式（學名藥、品牌）、配銷通路、全球預測 2024 - 2032 年Cephalosporin Drugs Market - By Generation (First, Second), Indication (Respiratory, UTI, STI, Gastrointestinal Infection), Route of Administration (Oral, Parenteral, Topical), Type (Generic, Branded), Distribution Channel, Global Forecast 2024 - 2032 |
||||||
在領先製藥公司越來越多的產品核准和臨床試驗的推動下，2024 年至 2032 年間，全球頭孢菌素藥物市場規模的複合年成長率將超過 3.1%。
為了重點對抗細菌感染和解決新出現的抗生素抗藥性，各公司正大力投資頭孢菌素藥物的研發。例如，2023年7月，Allecra Therapeutics揭露了向美國食品藥物管理局（FDA）提交的抗生素頭孢吡肟/恩美唑巴坦聯合使用的新藥申請（NDA）。該組合包括頭孢吡肟（第四代頭孢菌素）和恩美唑巴坦（一種專有的 BETA-內醯胺酶抑制劑）。
這些努力導致新配方獲得批准並擴大了現有藥物的適應症，推動了市場成長。此外，正在進行的探索頭孢菌素治療多種感染功效的臨床試驗進一步刺激了需求。隨著醫療保健提供者尋求有效的治療方案，信譽良好的公司提供的頭孢菌素藥物的供應量不斷增加，突顯了它們在應對與傳染病相關的全球健康挑戰方面的重要性。
整個頭孢菌素藥品產業根據產生、給藥途徑、類型、配銷通路和地區進行分類。
從 2024 年到 2032 年，第二代頭孢菌素細分市場將出現顯著的複合年成長率。由於其穿透組織和對抗抗藥性菌株的能力有所提高，第二代頭孢菌素正在成為醫療保健專業人員的首選。隨著細菌感染盛行率持續上升，抗生素抗藥性構成重大挑戰，對第二代頭孢菌素藥物的需求可能會持續成長，進而塑造醫藥市場的模式。
2024年至2032年，皮膚和軟組織感染領域的頭孢菌素類藥物市場佔有率將呈指數級成長。頭孢菌素抗生素通常用於治療金黃色葡萄球菌和化膿性鏈球菌等細菌病原體引起的 SSTI。它們對這些病原體的廣譜活性和功效使其成為治療 SSTI 的基石。由於人口老化和抗藥性細菌傳播等因素的推動，全球SSTI發生率持續上升，對頭孢菌素類藥物的需求仍然強勁。
到2032年，亞太地區頭孢菌素藥物市場將佔據主導地位。頭孢菌素因其對各種細菌病原體的功效而成為該地區廣泛使用的抗生素。此外，該地區不斷擴大的醫療基礎設施和改善醫療服務的可近性也有助於增加使用量。隨著亞太地區應對傳染病挑戰，對頭孢菌素藥物的需求可能會繼續呈上升趨勢，從而塑造該地區的製藥格局。例如，2023 年 3 月，國有政府製藥實體基本藥物有限公司 (EDCL) 在其博古拉工廠內建立了頭孢菌素部門，以實現孟加拉國藥品生產的自給自足。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 細菌感染的發生率增加
- 加強抗生素開發合作
- 越來越關注學名藥
- 產業陷阱與挑戰
- 抗生素抗藥性日益普遍
- 其他抗生素的激烈競爭
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按世代，2018 - 2032
- 主要趨勢
- 第一代頭孢菌素
- 第二代頭孢菌素
- 第三代頭孢菌素
- 第四代頭孢菌素
- 第五代頭孢菌素
第 6 章：市場估計與預測：按指標分類，2018 年 - 2032 年
- 主要趨勢
- 呼吸道感染
- 泌尿道感染（UTI）
- 皮膚和軟組織感染
- 性傳染感染（STI）
- 胃腸道感染
- 其他適應症
第 7 章：市場估計與預測：按管理途徑，2018 年 - 2032 年
- 主要趨勢
- 口服
- 注射用
- 專題
第 8 章：市場估計與預測：按藥物類型，2018 - 2032
- 主要趨勢
- 品牌化
- 通用的
第 9 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 10 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區
第 11 章：公司簡介
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Global Cephalosporin Drugs Market Size will witness over 3.1% CAGR between 2024 and 2032, propelled by the increasing number of product approvals and clinical trials conducted by leading pharmaceutical companies.
With a focus on combating bacterial infections and addressing emerging antibiotic resistance, companies are investing heavily in the research and development of cephalosporin drugs. For instance, in July 2023, Allecra Therapeutics disclosed the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a combination antibiotic, cefepime/enmetazobactam. This combination includes cefepime, a fourth-generation cephalosporin, and enmetazobactam, a proprietary beta-lactamase inhibitor.
These efforts have resulted in the approval of new formulations and expanded indications for existing drugs, driving market growth. Moreover, ongoing clinical trials exploring the efficacy of cephalosporins in treating a wide range of infections further fuel demand. As healthcare providers seek effective treatment options, the rising availability of cephalosporin drugs from reputable companies underscores their importance in addressing global health challenges related to infectious diseases.
The overall Cephalosporin Drugs Industry is classified based on the generation, route of administration, type, distribution channel, and region.
The second generation cephalosporin segment will register a significant CAGR from 2024 to 2032. These antibiotics offer enhanced efficacy against a broad spectrum of bacterial infections, including respiratory and urinary tract infections. With their improved ability to penetrate tissues and combat resistant strains, second-generation cephalosporins are becoming a preferred choice for healthcare professionals. As the prevalence of bacterial infections continues to rise and antibiotic resistance poses a significant challenge, the demand for second-generation cephalosporin drugs could continue growing, shaping the landscape of the pharmaceutical market.
The cephalosporin drugs market share from the skin and soft tissue infection segment will witness an exponential growth rate from 2024-2032. Cephalosporin antibiotics are commonly prescribed to treat SSTIs caused by bacterial pathogens such as Staphylococcus aureus and Streptococcus pyogenes. Their broad-spectrum activity and efficacy against these pathogens make them a cornerstone in the treatment of SSTIs. As the incidence of SSTIs continues to rise globally, driven by factors such as aging populations and the spread of antibiotic-resistant bacteria, the demand for cephalosporin drugs remains robust.
Asia Pacific cephalosporin drugs market will dominate the market share through 2032. Factors such as population growth, increasing urbanization, and a rising incidence of bacterial infections are driving this demand. Cephalosporins are widely prescribed antibiotics in the region due to their efficacy against various bacterial pathogens. In addition, the region's expanding healthcare infrastructure and improving access to medical services contribute to increased usage. As Asia Pacific grapples with infectious disease challenges, the demand for cephalosporin drugs could continue its upward trajectory, shaping the pharmaceutical landscape in the region. For instance, in March 2023, the Essential Drugs Company Limited (EDCL), a state-owned government pharmaceuticals entity, established a Cephalosporin Unit within its Bogura plant to achieve self-sufficiency in drug manufacturing in Bangladesh.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of bacterial infections
- 3.2.1.2 Growing collaborations for development of antibiotics
- 3.2.1.3 Increasing focus on generic medications
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Increasing prevalence of antibiotic resistance
- 3.2.2.2 High competition from other antibiotics
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Generation, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 First generation cephalosporins
- 5.3 Second generation cephalosporins
- 5.4 Third generation cephalosporins
- 5.5 Fourth generation cephalosporins
- 5.6 Fifth generation cephalosporins
Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Respiratory infections
- 6.3 Urinary tract infections (UTIs)
- 6.4 Skin and soft tissue infections
- 6.5 Sexually transmitted infections (STIs)
- 6.6 Gastrointestinal infections
- 6.7 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Topical
Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Branded
- 8.3 Generic
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Hospital pharmacy
- 9.3 Retail pharmacy
- 9.4 Online pharmacy
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 AbbVie Inc.
- 11.2 Bristol-Myers Squibb Company
- 11.3 Eli Lilly and Company
- 11.4 F. Hoffmann-La Roche Ltd.
- 11.5 Merck & Co., Inc.
- 11.6 Mylan N.V.
- 11.7 Novartis AG
- 11.8 Pfizer Inc.
- 11.9 Sanofi
- 11.10 Sun Pharmaceutical Industries Ltd.
- 11.11 Teva Pharmaceutical Industries Ltd.
